ArticleJournal of Yeungnam medical science2026
Extended therapeutic efficacy of dacarbazine following prior treatment with immune checkpoint inhibitors in metastatic melanoma: a single center retrospective study in Korea.
Article in Journal of Yeungnam medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced malignant melanoma. This study examined the real-world efficacy of dacarbazine in patients who had previously received pembrolizumab, based on the hypothesis that prior ICI treatment enhances the therapeutic response to subsequent chemotherapy.
methodsThis retrospective study included 71 patients with histologically confirmed malignant melanoma treated at Kyungpook National University Chilgok Hospital (Daegu, Korea) between 2011 and 2023. The patients received dacarbazine for unresectable stage IIIC, IIID, or IV melanoma (American Joint Committee on Cancer, 8th edition).
resultsAmong the 71 patients, the median patient age was 64 years (range, 25-89 years). When categorized by melanoma subtype, 18 patients (25.4%) had acral melanoma, 40 (56.3%) had cutaneous melanoma, and 13 (18.3%) had mucosal melanoma. Sixteen of the dacarbazine-treated patients had not received pembrolizumab previously (DTI-only group), while 55 had (pem-DTI group). The median progression-free survival was 2.3 months in the DTI-only group and 3.9 months in the pem-DTI group (hazard ratio [HR], 0.246; 95% confidence interval [CI], 0.106-0.576; p=0.001). The median overall survival was 6.8 months in the DTI-only group and 19.0 months in the pem-DTI group (HR, 0.198; 95% CI, 0.068-0.574; p=0.003). The duration of response (DoR) was 4.64 months in the DTI group and 8.11 months in the pem-DTI group.
conclusionThis study demonstrated that the DoR to dacarbazine was prolonged following ICI therapy (4.64 months vs. 8.11 months). This indicates that prior ICI treatment may enhance tumor sensitivity to chemotherapy, making dacarbazine a viable option for treating refractory, relapsed, or progressive melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.